Cartesian Therapeutics (RNAC) Common Equity (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Common Equity of -$148.1 million for Q1 2026, down 579.78% year-over-year from $30.9 million in Q1 2025, and down 17.33% quarter-over-quarter from -$126.2 million in Q4 2025.
Cartesian Therapeutics (RNAC) Common Equity (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Common Equity for 12 consecutive years, with -$148.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 579.78% year-over-year to -$148.1 million; the TTM figure through Mar 2026 stood at -$148.1 million (down 579.78% YoY), while the FY2025 annual figure was -$126.2 million, down 1755.92% from the prior year.
- Common Equity slipped to -$148.1 million in Q1 2026 per RNAC's latest filing, from -$126.2 million in the prior quarter.
- Across five years, Common Equity topped out at $93.8 million in Q4 2022 and bottomed at -$440.2 million in Q4 2023.
- Historically, Common Equity has averaged -$27.9 million across 5 years, with a median of -$2.5 million in 2025.
- Annual changes were most pronounced in 2022 — Common Equity soared 2222.36% — and 2025, when it slumped 4866.49%.
- Cartesian Therapeutics' Common Equity stood at $93.8 million in 2022, then tumbled by 569.14% to -$440.2 million in 2023, then surged by 98.45% to -$6.8 million in 2024, then slumped by 1755.92% to -$126.2 million in 2025, then fell by 17.33% to -$148.1 million in 2026.
- Business Quant data shows RNAC's Common Equity at -$148.1 million in Q1 2026, -$126.2 million in Q4 2025, and -$35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | -125.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -125.23 Mn |
| Mar 31, 2026 | -148.12 Mn |
| Dec 31, 2025 | -126.24 Mn |
| Sep 30, 2025 | -35.84 Mn |
| Jun 30, 2025 | -2.53 Mn |
| Mar 31, 2025 | -21.79 Mn |
| Dec 31, 2024 | -6.80 Mn |
| Sep 30, 2024 | 752,000.00 |
| Jun 30, 2024 | -101.46 Mn |
| Mar 31, 2024 | -116.80 Mn |
| Dec 31, 2023 | -440.18 Mn |
| Sep 30, 2023 | 60.33 Mn |
| Jun 30, 2023 | 65.45 Mn |
| Mar 31, 2023 | 74.58 Mn |
| Dec 31, 2022 | 93.83 Mn |
| Sep 30, 2022 | 84.91 Mn |
| Jun 30, 2022 | 89.61 Mn |
| Mar 31, 2022 | 55.76 Mn |
| Dec 31, 2021 | 22.52 Mn |
| Sep 30, 2021 | -18.73 Mn |